Breaking News Instant updates and real-time market news.

SGEN

Seattle Genetics

$63.12

-0.87 (-1.36%)

, CTAS

Cintas

$239.46

-3.85 (-1.58%)

18:50
07/16/19
07/16
18:50
07/16/19
18:50

Fly Intel: After Hours Movers

UP AFTER EARNINGS: Seattle Genetics (SGEN) up 7.6%... Cintas (CTAS) up 5.4%... United Airlines (UAL) up 0.3%. ALSO HIGHER: Qualcomm (QCOM) up 5.6% after DOJ requested halt of antitrust ruling against company. DOWN AFTER EARNINGS: Nu Skin (NUS) down 17.6% after cutting Q2 and FY19 guidance... Senseonics (SENS) down 7.7% after equity offering... CSX (CSX) down 6.2%... Interactive Brokers (IBKR) down 1.5%. ALSO LOWER: Inovio (INO) down 7.3% after cutting workforce by 28% and prioritizing commercial development of its late-stage HPV assets... Tellurian (TELL) down 1.8% after being cut to Hold at Stifel... Weibo (WB) down 1.1% after being downgraded to Neutral at Credit Suisse. Movers as of 18:30ET.

SGEN

Seattle Genetics

$63.12

-0.87 (-1.36%)

CTAS

Cintas

$239.46

-3.85 (-1.58%)

UAL

United Continental

$94.00

2.7 (2.96%)

QCOM

Qualcomm

$75.66

0.23 (0.30%)

NUS

Nu Skin

$45.50

1.44 (3.27%)

SENS

Senseonics

$1.68

-0.075 (-4.29%)

CSX

CSX

$79.57

1.05 (1.34%)

IBKR

Interactive Brokers

$50.72

-0.44 (-0.86%)

INO

Inovio

$3.00

0.05 (1.69%)

TELL

Tellurian

$7.68

-0.1 (-1.29%)

WB

Weibo

$41.57

-1.47 (-3.42%)

  • 16

    Jul

  • 16

    Jul

  • 16

    Jul

  • 16

    Jul

  • 16

    Jul

  • 17

    Jul

  • 17

    Jul

  • 31

    Jul

  • 06

    Aug

  • 07

    Aug

  • 26

    Aug

  • 09

    Sep

  • 13

    Nov

  • 18

    Jul

SGEN Seattle Genetics
$63.12

-0.87 (-1.36%)

04/10/19
STFL
04/10/19
INITIATION
Target $70
STFL
Hold
Seattle Genetics initiated with a Hold at Stifel
Stifel analyst Stephen Willey initiated Seattle Genetics with a Hold rating and a price target of $70, saying that while the company "commands a leadership position in the development of antibody-drug conjugate technology", the current ADCETRIS estimates as "much-too-optimistic" in suggesting trajectory to sales of over $1B. The analyst adds that although the "recently-announced phase data for enfortumab vedotin will initiate Seattle Genetics' transition to a multi-product commercial company", he sees the "presumption of clinical/commercial success to be appropriately risk-adjusted in the stock at these levels."
04/25/19
PIPR
04/25/19
NO CHANGE
Target $64
PIPR
Neutral
Seattle Genetics Q1 marks third quarter of 'sluggish growth', says Piper Jaffray
Piper Jaffray analyst Joseph Catanzaro is keeping his Neutral rating and $64 price target on Seattle Genetics after its Q1 results that saw Adcetris sales of $135M missing consensus of $141M. The analyst notes that this marks the 3rd consecutive quarter of "sluggish growth", also lowering his FY19 EPS outlook to ($1.05) from (94c) and FY20 outlook to (14c) from 12c. Catanzaro lowers his FY19 Adcetris sales forecast to $611M from $633M, adding that the company's Adcentris revenue outlook of $610M-$640M for this year may "prove difficult."
03/27/19
BREN
03/27/19
INITIATION
Target $95
BREN
Buy
Seattle Genetics initiated with a Buy at Berenberg
Berenberg analyst Shanshan Xu initiated Seattle Genetics with a Buy and $95 price target saying he sees further appreciation following strong performance over the past 12 months. Xu believes several assets are undervalued at current levels including tucatinib in Phase III development for breast cancer, and enfortumab in Phase III development for urothelial carcinoma. Further, the analyst believes the receipt of a Complete Response Letter for the Biologics License Application for lead product candidate IMMU-132 for breast cancer may be resolved following an inspection by the FDA in second half 2019.
03/28/19
PIPR
03/28/19
NO CHANGE
PIPR
Neutral
Seattle Genetics' ORR 'impressive' for third-line UBC, says Piper Jaffray
After Seattle Genetics (SGEN) reported topline results from the first cohort of patients in a phase 2 trial evaluating enfortumab vedotin for the treatment of patients with locally advanced or metastatic urothelial cancer who have received two prior lines of treatment, Piper Jaffray analyst Joseph Catanzaro said the 44% objective response rate, or ORR, was "impressive" in this population of patients. While he thinks there may be room for upward revisions to his assumptions, he prefers to wait for the full data set before making any changes. Catanzaro keeps a Neutral rating on Seattle Genetics, citing his concerns about the growth of Adcetris.
CTAS Cintas
$239.46

-3.85 (-1.58%)

03/22/19
JPMS
03/22/19
NO CHANGE
Target $235
JPMS
Overweight
Cintas price target raised to $235 from $210 at JPMorgan
JPMorgan analyst Andrew Steinerman raised his price target for Cintas to $235 from $210 saying the company "remains well on the growth track" despite the Q3 "hiccup" due to weather. The analyst expects the stock to decline after last night's results, but remains bullish on Cintas given the company's "innovation, discipline, and market leadership." He keeps an Overweight rating on the name.
01/03/19
01/03/19
UPGRADE

Buy
Cintas upgraded to Buy on valuation at BofA/Merrill
As previously reported, BofA/Merrill upgraded Cintas to Buy from Neutral an increased its price target to $192 from $188. Analyst Gary Bisbee views the recent pullback in shares as a buying opportunity for this strong growth franchise with a record of earnings growth in the mid teens and business momentum that remains positive.
06/20/19
WBLR
06/20/19
NO CHANGE
WBLR
Cintas near-term upside limited on 'aggressive' estimates, says William Blair
William Blair analyst Tim Mulrooney says that while he expects Cintas to outperform the broader market over the long term, the stock's near-term upside will be limited as fiscal 2020 consensus figures "appear aggressive." Further, some uniform rental customers are likely under pressure from trade-related issues while May payroll growth was "underwhelming," Mulrooney tells investors in a research note. The analyst keeps an Outperform rating on Cintas but is cautious on the company's fiscal 2020 guidance and notes the stock's valuation is near its all-time high.
06/17/19
BARD
06/17/19
NO CHANGE
BARD
Outperform
Cintas named new 'Bearish Fresh Pick' at Baird
Baird analyst Andrew Wittmann said in a note to investors before the open that his uniform rental survey for the second quarter showed that strong textile rental trends continue and he believes uniform fundamentals remain solid. Despite the positive outlook on stocks in the sector, Wittmann said he would lighten Cintas (CTAS) positions into earnings and named the stock a new "Fresh Pick-Bearish," noting its shares are already trading above his price target and that initial FY20 guidance will be issued by management with a "historically conservative" approach. Wittman keeps Outperform ratings on Cintas, Aramark (ARMK) and UniFirst (UNF) and said he remains positive on the latter two stock.
UAL United Continental
$94.00

2.7 (2.96%)

06/06/19
06/06/19
UPGRADE

Fly Intel: Top five analyst upgrades
Catch up on today's top five analyst upgrades with this list compiled by The Fly: 1. AMD (AMD) upgraded to Equal Weight from Underweight at Morgan Stanley with analyst Joseph Moore saying he still remains concerned that consensus forecasts for AMD in the second half of 2019 are too high, Moore acknowledges that "being cautious on the stock has obviously been the wrong call." 2. United Continental (UAL) upgraded to Buy from Neutral at Goldman Sachs with analyst Catherine O'Brien saying she sees a better risk/reward for the shares relative to Spirit Airlines (SAVE), a stock she downgraded this morning to Neutral from Buy. 3. Digital Realty (DLR) upgraded to Outperform from Market Perform at Raymond James with analyst Frank Louthan saying after he met with management, he now sees Digital Realty being poised to reverse recent underperformance compared to the group, contending that its diversified base should be a strength. 4. Outfront Media (OUT) upgraded to Outperform from In-Line at Imperial Capital with analyst David Miller saying he increased his estimates for fiscal 2019 and 2020 due the company's share gains against other forms of media. His higher estimates for 2020 are due to a "more robust" outlook for Outfront's transit business, particularly digital signage in New York City. 5. Flex (FLEX) upgraded to Conviction Buy from Neutral at Goldman Sachs with analyst Mark Delaney saying he had been concerned about the potential overhang from a "handful of issues," including the company's CEO search, the size of its CTG program exits and the resulting impact on earnings, and macroeconomic risk. He believes, however, that these issues now have more clarity and are priced into the stock. This list is just a portion of The Fly's full analyst coverage. To see The Fly's full Street Research coverage, click here.
06/13/19
JPMS
06/13/19
NO CHANGE
JPMS
American, Southwest raised domestic rates in last two days, says JPMorgan
JPMorgan analyst Jamie Baker said American Airlines (AAL) took a "plain vanilla" domestic fare increase of $5 one-way yesterday morning, which was followed by what looks like a system-wide increase from Hawaiian (HA) and a "substantive" Lower 48 increase from Southwest (LUV). He was not expecting another increase so soon after the industry took a broad-based domestic increase in the second week of May, noted Baker, who thinks evidence of domestic demand and potential Q2 guidance increases could reverse "recent apathy" towards the airline space. Other publicly traded airlines include Alaska Air (ALK), American Airlines (AAL), Delta Air Lines (DAL), JetBlue (JBLU), Southwest (LUV), Spirit Airlines (SAVE) and United Continental (UAL).
06/13/19
JPMS
06/13/19
NO CHANGE
JPMS
JPMorgan notes airline fare hike, doesn't see domestic 'resilience' as priced in
JPMorgan analyst Jamie Baker said he was "surprised" to see domestic fares rising again after a price hike five weeks ago, noting that Southwest (LUV) joined with an increase overnight. Given "the crescendo of inquiries as to why, and nary a question on fares," Baker said he is confident that increased domestic fare resilience is not yet priced into airline stocks. Other publicly traded airlines include Alaska Air (ALK), American Airlines (AAL), Delta Air Lines (DAL), JetBlue (JBLU), Spirit Airlines (SAVE) and United Continental (UAL).
06/06/19
GSCO
06/06/19
DOWNGRADE
Target $60
GSCO
Neutral
Spirit Airlines downgraded to Neutral from Buy at Goldman Sachs
Goldman Sachs analyst Catherine O'Brien downgraded Spirit Airlines (SAVE) to Neutral from Buy and lowered her price target for the shares to $69 from $69. The analyst coupled the downgrade with an upgrade of United Continental Holdings (UAL) to Buy from Neutral. There is downside risk to the consensus earnings forecasts for Spirit while United's estimates have appropriately incorporated tougher second half 2019 comparables, O'Brien tells investors in a research note. The analyst is now less confident that Spirit's initiatives will ramp up enough in the back half of 2019 to offset the "materially tougher" comparables the company faces.
QCOM Qualcomm
$75.66

0.23 (0.30%)

06/06/19
LEHM
06/06/19
NO CHANGE
Target $90
LEHM
Overweight
Qualcomm price target lowered to $90 from $100 at Barclays
Barclays analyst Blayne Curtis lowered his price target for Qualcomm to $90 from $100 to reflect the removal of Huawei from his model. The analyst, however, keeps an Overweight rating on the shares.
07/12/19
MZHO
07/12/19
NO CHANGE
Target $68
MZHO
Neutral
Qualcomm price target raised to $68 from $65 at Mizuho
Mizuho analyst Vijay Rakesh raised his price target for Qualcomm to $68 from $65 citing improved multiples in the semiconductor space. The analyst, however, reiterates a Neutral rating on the shares. The company's near-term outlook "could be soft" given weak handsets trends and potentially lower 5G royalty rates in the second half of 2019, Rakesh tells investors in a research note.
06/18/19
MSCO
06/18/19
NO CHANGE
Target $95
MSCO
Overweight
Qualcomm share ownership 'still worth the noise,' says Morgan Stanley
Morgan Stanley analyst James Faucette said being a Qualcomm (QCOM) shareholder has "always required a bit more mettle" given its history of political and legal risks, but he thinks that at current levels the stock is "still worth the noise." Faucette reduced his FY19 and FY20 estimates slightly because he no longer assumes Apple (AAPL) will refresh its portfolio to include more Qualcomm-based legacy models in late 2019 and most of FY20 and also to be more conservative in his assumption of Huawei's contribution. However, he is now modeling more impact from an uplift in 5G average selling prices and thinks if Huawei handsets are absorbed by other OEMs that Qualcomm could see a positive impact, Faucette noted. The analyst, who projects Qualcomm's FY21 earnings at about $6.80 per share, keeps an Overweight rating and $95 price target on the stock.
06/11/19
RAJA
06/11/19
NO CHANGE
RAJA
Broadcom, Apple deal closes door on Qualcomm/Qorvo, says Raymond James
Raymond James analyst Chris Caso notes that Broadcom (AVGO) disclosed that it had signed a 2-year contract with Apple (AAPL) for the sale of RF components, similar to a 3-year contract between Broadcom and Apple signed in 2016 but now with the latter sourcing "all of its requirements for such RF front end components and modules" from Broadcom. The analyst believes this closes the door on Qualcomm (QCOM) getting RF content in the 2020 iPhone, while maintaining the status quo for Skyworks (SWKS), which supplied the low band PAD and diversity receive through the term of the last Broadcom/Apple contract. Additionally, Caso thinks the Broadcom agreement also closes the door on the mid/high band opportunity at Apple for Qorvo (QRVO) through 2020.
NUS Nu Skin
$45.50

1.44 (3.27%)

07/03/19
STFL
07/03/19
NO CHANGE
Target $45
STFL
Sell
Stifel keeps Sell on Nu Skin after Usana cuts outlook on China
Nu Skin Enterprises (NUS) competitor Usana last night announced preliminary Q2 results with sales 17% below consensus and the company also lowered full year sales and earnings guidance 16% and 25%, respectively, at the midpoint, Stifel analyst Mark Astrachan tells investors in a research note. Usana's downside is largely due to softer than expected sales in China, which the company expects will continue throughout 2019, the analyst adds. He points out that increased promotional activity in China did not generate meaningful sales and customer growth. Astrachan says this is consistent with the risks noted in his downgrade of Nu Skin shares to Sell. The analyst is now more cautious on China and keeps a Sell rating on Nu Skin shares with a $45 price target.
04/03/19
STFL
04/03/19
NO CHANGE
Target $43
STFL
Sell
Stifel reiterates Sell rating on Nu Skin after Usana profit warning
After Usana (USNA) announced softer than expected preliminary Q1 results, which it attributed to sales in China and unfavorable media coverage on the direct selling industry there, Stifel analyst Mark Astrachan reiterated his Sell rating and $43 price target on shares of competitor Nu Skin (NUS). Despite Nu Skin having less exposure to nutrition than Usana, Astrachan continues to worry about increasing scrutiny on Nu Skin and thinks the potential for a more thorough investigation by the Chinese government remains a risk.
05/01/19
DBAB
05/01/19
UPGRADE
Target $73
DBAB
Buy
Deutsche Bank upgrades Nu Skin to Buy on reduced China risk
Deutsche Bank analyst Faiza Alwy upgraded Nu Skin Enterprises to Buy from Hold and raised her price target for the shares to $73 from $64. The analyst sees "materially" lower China risk following the company's Q1 results. Despite having to limit certain business meetings in China for at least a 100-day period while the regulatory authorities conducted an industry-wide investigation regarding product claims, Nu Skin delivered 12% Mainland China sales growth, Alwy tells investors in a post-earnings research note.
05/01/19
DBAB
05/01/19
UPGRADE
DBAB
Buy
Nu Skin upgraded to Buy from Hold at Deutsche Bank
SENS Senseonics
$1.68

-0.075 (-4.29%)

07/05/19
07/05/19
NO CHANGE

Fly Intel: Top five analyst actions
Catch up on today's top five analyst actions with this list compiled by The Fly: 1. Teva (TEVA) upgraded to Buy from Hold at Argus with analyst Jason McCarthy saying the company has been making progress in resolving its "numerous challenges" of the past several years. 2. Senseonics (SENS) downgraded to Market Perform from Outperform at Raymond James with analyst Jayson Bedford stating the company's "persistent headwinds" leave him "less patient" with respect to the shares. 3.Omnova Solutions (OMN) downgraded to Hold from Buy at Deutsche Bank with analyst David Begleiter saying he believes Synthomer paid a "fair but full price" to acquire Omnova and that a competing bidder is unlikely to emerge. 4. Mercer (MERC) downgraded to Neutral from Outperformer at CIBC. 5. BASF (BASFY) initiated with a Neutral at Goldman Sachs. This list is just a portion of The Fly's full analyst coverage. To see The Fly's full Street Research coverage, click here.
07/05/19
RAJA
07/05/19
DOWNGRADE
RAJA
Market Perform
Senseonics downgraded to Market Perform from Outperform at Raymond James
Raymond James analyst Jayson Bedford downgraded Senseonics to Market Perform from Outperform. The analyst says the company's "persistent headwinds" leave him "less patient" with respect to the shares.
02/04/19
PIPR
02/04/19
NO CHANGE
Target $2.7
PIPR
Neutral
Piper Jaffray uncertain of benefits from increased Roche access for Senseonics
Piper Jaffray analyst JP Kim kept his Neutral rating and $2.70 price target on Senseonics (SENS) after the company announced an extension of agreement with Roche (RHHBY). The analyst notes that the management is likely willing to trade off the near term price gains for long term volume gain through this deal, but adds that a reset of consensus estimates for sales that would lead to Senseonics becoming a "beat and raise story" is uncertain.
06/06/19
PIPR
06/06/19
NO CHANGE
PIPR
Senseonics receives FDA claim for Eversense CGM system, says Piper Jaffray
Piper Jaffray analyst JP McKim maintained a Neutral rating and $2.70 price target on Senseonics, while noting that the company "received a non-adjunctive claim for their Eversense CGM system" from the FDA. The analyst said that the claim would allow Eversense "to be used in replacement for finger stick glucose measurements" and added that it "is a needed claim to begin the process to unlock the Medicare population and represents an important stage in their commercialization process."
CSX CSX
$79.57

1.05 (1.34%)

07/10/19
GSCO
07/10/19
INITIATION
Target $86
GSCO
Neutral
CSX initiated with a Neutral at Goldman Sachs
Goldman Sachs analyst Jordan Alliger started CSX with a Neutral rating and $86 price target. The analyst sees more margin and earnings upside potential at companies in the earlier stage of PSR adoption.
07/10/19
07/10/19
DOWNGRADE

Hold
CSX, Canadian Pacific downgraded to Hold from Buy at Loop Capital
As previously reported, Loop Capital analyst Rick Paterson downgraded CSX (CSX) and Canadian Pacific (CP) to Hold from Buy as part of a broader Air Freight & Logistics industry research note, saying the freight transportation data continue to indicate a slowing in the industrial economy. The analyst cites volumes registering a second consecutive quarter of negative growth relative to their prior years, with the most recent quarter also declining sequentially from the prior one and the upcoming quarter likely remaining pressured by the tough annual comps. The analyst also lowers his price targets on Canadian Pacific to C$338 from C$340, CSX to $81 from $85 while also reducing the price targets on UPS (UPS) to $128 from $145, J.B. Hunt (JBHT) to $121 from $133, and Hub Group (HUBG) to $65 from $71.
06/13/19
LEHM
06/13/19
DOWNGRADE
Target $170
LEHM
Equal Weight
Union Pacific downgraded to Equal Weight from Overweight at Barclays
Barclays analyst Brandon Oglenski downgraded Union Pacific (UNP) to Equal Weight from Overweight and lowered his price target for the shares to $170 from $190. The analyst also cut his Transportation sector view to Neutral saying he sees "real fundamental challenges set against high market expectations." Railroad equities are not properly discounting recent headwinds from softer demand and "lower supply chain urgency" across North America, Oglenski tells investors in a research note. Further, he sees increasing risk that tariff driven inflation could "damp consumer consumption" later this year, at least in the U.S. As a result, Oglenski suggests investors take some Transportation exposure off the table. He keeps Equal Weight ratings on Canadian National (CNI), Kansas City Southern (KSU) and Norfolk Southern (NSC) as well as Overweight ratings on Canadian Pacific (CP) and CSX (CSX).
07/10/19
LOOP
07/10/19
DOWNGRADE
LOOP
Hold
CSX downgraded to Hold from Buy at Loop Capital
Loop Capital analyst Rick Paterson downgraded CSX to Hold from Buy.
IBKR Interactive Brokers
$50.72

-0.44 (-0.86%)

11/30/18
GSCO
11/30/18
INITIATION
Target $58
GSCO
Neutral
Interactive Brokers initiated with a Neutral at Goldman Sachs
Goldman Sachs analyst Will Nance initiated coverage of the Online Brokers with an Attractive coverage view, stating that for the group on the whole he believes cyclical factors will drive fundamentals and valuation in the near term despite organic growth and pricing concerns. He started Interactive Brokers with a Neutral rating and $58 price target, stating that he views it as the most cyclically exposed among the group. Over time, he expects the growth in its white label introducing brokers channel will continue to drive a mix shift towards NII and away from commissions, Nance added.
12/10/18
WELS
12/10/18
NO CHANGE
Target $46
WELS
Underperform
Interactive Brokers price target lowered to $46 from $52 at Wells Fargo
Wells Fargo analyst Christopher Harris lowered his price target for Interactive Brokers to $46 from $52 saying growth is slowing. The analyst remains cautious on the stock given the weakening trends in its core business, its exposure to Asia and its high relative valuation. He reiterates an Underperform rating on the shares.
07/18/18
RHCO
07/18/18
NO CHANGE
Target $71
RHCO
Hold
Interactive Brokers price target lowered to $71 from $75 at SunTrust
SunTrust analyst Douglas Mewhirter lowered his price target on Interactive Brokers to $71 and kept his Hold rating after its mixed Q2 results. The analyst notes the company posted slower account growth and Daily Average Revenue Trades metrics, even as its net interest income improved and its profits benefited from the lower tax rate. As a result of the lower forecasted commissions revenues, Mewhirter also lowers his Interactive Brokers' FY18 EPS estimate to $2.16 from $2.23.
INO Inovio
$3.00

0.05 (1.69%)

05/30/19
SBSH
05/30/19
NO CHANGE
Target $7
SBSH
Buy
Inovio risk/reward attractive into data readouts, says Citi
Citi analyst Joel Beatty lowered his price target for Inovio Pharmaceuticals (INO) to $7 from $10 after AstraZeneca (AZN) decided to discontinue activities with respect to its rights to co-develop up to two new DNA-based cancer vaccine product candidates. The analyst, however, says this is a good time to buy shares of Inovio. The company has three phase 1/2 immuno-oncology combo trials expected to readout in the second half of 2019, and the stock's risk/reward is attractive into the news, Beatty tells investors in a research note.
05/29/19
CANT
05/29/19
NO CHANGE
Target $12
CANT
Overweight
Inovio milestones from Astra still worth up to $250M, says Cantor Fitzgerald
Inovio (INO) announced that it received notification from MedImmune, a subsidiary of AstraZeneca (AZN), that it plans to discontinue research collaboration programs except for the MEDI0457/ durvalumab combo studies that are in multiple Phase 2 trials in patients with HPV associated cancers, Cantor Fitzgerald analyst Charles Duncan tells investors in a research note. Despite "strained optics," the collaboration change makes sense, says the analyst. He estimates Inovio's MEDI0457 milestones are worth up to $250M and keeps an Overweight rating on the shares with a $12 price target.
05/29/19
HCWC
05/29/19
NO CHANGE
HCWC
Buy
AstraZeneca decision does not impact MEDI0457, says H.C. Wainwright
H.C. Wainwright analyst Raghuram Selvaraju says AstraZeneca's (AZN) decision to discontinue activities related to two new DNA-based cancer vaccine candidates from Inovio (INO) does not affect MEDI0457. AstraZeneca continues to pursue the development of MEDI0457, which is being evaluated in combination with durvalumab in multiple Phase 2 studies in HPV-related cancers, Selvaraju tells investors in a research note. Inovio is eligible to receive up to $700M potential milestone payments, including $250M related to MEDI0457, says the analyst. He reiterates a Buy rating on Inovio with a $13 price target.
05/09/19
05/09/19
NO CHANGE

Inovio reports Q1 EPS (30c), consensus (26c)
Reports Q1 revenue $2.8M, consensus $6.41M.
TELL Tellurian
$7.68

-0.1 (-1.29%)

05/13/19
GABE
05/13/19
INITIATION
GABE
Buy
Tellurian initiated with a Buy at Gabelli
Gabelli analyst Matthew Trusz started Tellurian with a Buy rating and $14 private market value estimate. The analyst views the company's equity-partnership model as unique to the U.S. market, and says it is further differentiated by its willingness to take commodity price risk.
07/16/19
STFL
07/16/19
DOWNGRADE
STFL
Hold
Tellurian downgraded to Hold from Buy at Stifel
Stifel analyst Benjamin Nolan downgraded Tellurian to Hold from Buy and lowered his price target on shares to $9 from $16. The analyst said he sees growth in LNG production limiting gas price upside, and pointed out that lower gas prices longer term would "have a negative impact on Tellurian's marketing margins and consequently their discounted cash flows." Nolan concluded that with a "dampened view on LNG prices," he no longer believes the shares offer "a risk/reward worth taking."
03/11/19
BTIG
03/11/19
INITIATION
Target $20
BTIG
Buy
Tellurian initiated with a Buy at BTIG
BTIG analyst Gregory Lewis started Tellurian with a Buy rating and $20 price target. The company plans to build an integrated natural gas company with first gas targeted for 2023, Lewis tells investors in a research note. The analyst calls Tellurian a "story stock" that he expects to become an "execution stock" as it receives final FERC approval and takes Final Investment Decision by the middle of 2019.
03/12/19
03/12/19
INITIATION

Fly Intel: Top five analyst initiations
Catch up on today's top five analyst initiations with this list compiled by The Fly: 1. Snap (SNAP) initiated with an Overweight at Consumer Edge. 2. Crinetics (CRNX) initiated with an Overweight at Cantor Fitzgerald. 3. Tellurian (TELL) initiated with a Buy at BTIG. 4. Stealth Biotherapeutics (MITO) initiated with an Outperform at Evercore ISI, a Buy at Nomura Instinet, and a Hold at Jefferies. 5. Resideo (REZI) initiated with an Outperform at Imperial Capital. This list is just a portion of The Fly's analyst coverage. To see The Fly's full Street Research coverage, click here.
WB Weibo
$41.57

-1.47 (-3.42%)

05/28/19
05/28/19
DOWNGRADE

Fly Intel: Top five analyst downgrades
Catch up on today's top five analyst downgrades with this list compiled by The Fly: 1. Gilead (GILD) downgraded to Sell from Neutral at Goldman Sachs with analyst Terence Flynn saying he expects Gilead's sales growth to decelerate saying the Truvada/Atripla loss of exclusivities in September 2020 represents a $3B headwind. 2. Teva (TEVA) downgraded to Neutral from Buy at UBS with analyst Navin Jacob saying he sees larger potential litigation expense following the company's settlement with Oklahoma as well as later than expected launches on its generic pipeline assets. 3. Weibo (WB) downgraded to Neutral from Overweight at JPMorgan with analyst Binbin Ding sayin ghe sees a worsening advertising outlook in the near-term with "no clear visibility" into the second half of 2019 and 2020. 4. Nutanix (NTNX) downgraded to Equal Weight from Overweight at Morgan Stanley with analyst Katy Huberty saying the combination of slowing industry demand and competition from Dell (DELL) will slow down a full recovery in its business. 5. Roku (ROKU) downgraded to Equal Weight from Overweight at Stephens with analyst Kyle Evans saying though he remains "very positive" on Roku over the long-term, he believes the stock's recently increased valuation combined with raised expectations creates increased near-term risk. This list is just a portion of The Fly's full analyst coverage. To see The Fly's full Street Research coverage, click here.
07/16/19
FBCO
07/16/19
DOWNGRADE
FBCO
Neutral
Weibo downgraded to Neutral from Outperform at Credit Suisse
06/28/19
JPMS
06/28/19
DOWNGRADE
Target $3.5
JPMS
Underweight
JPMorgan cautious on China ad recovery, downgrades Sogou, cuts Baidu target
JPMorgan analyst Alex Yao last night downgraded Sogou (SOGO) to Underweight from Neutral and lowered his price target for the shares to $3.50 from $5.50. The analyst says he found no evidence to support the "widely adopted optimism" on an advertising growth recovery in the second half of 2019 for the China Internet sector. As a result, he's cautious on names with high exposure to online ads, or Baidu (BIDU), Weibo (WB), Sogou, Focus Media, Autohome (ATHM), and Bitauto (BITA). Yao downgraded both Sogou and Focus Media to Underweight and lowered his price target for Neutral-rated Baidu to $120 from $150.
05/28/19
JPMS
05/28/19
DOWNGRADE
Target $45
JPMS
Neutral
Weibo downgraded to Neutral from Overweight at JPMorgan
JPMorgan analyst Binbin Ding downgraded Weibo to Neutral from Overweight and lowered his price target for the shares to $45 from $68. The analyst sees a worsening advertising outlook in the near-term with "no clear visibility" into the second half of 2019 and 2020.

TODAY'S FREE FLY STORIES

DB

Deutsche Bank

$6.98

-0.19 (-2.65%)

, COF

Capital One

$83.06

-2.68 (-3.13%)

17:57
08/23/19
08/23
17:57
08/23/19
17:57
Periodicals
Deutsche Bank, Capital One won't say if they have Trump's tax returns, NYP says »

Deutsche Bank (DB) and…

DB

Deutsche Bank

$6.98

-0.19 (-2.65%)

COF

Capital One

$83.06

-2.68 (-3.13%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 27

    Oct

MXIM

Maxim Integrated

$52.14

-2.42 (-4.44%)

17:53
08/23/19
08/23
17:53
08/23/19
17:53
Hot Stocks
Maxim Integrated's Jain sells 12,683 common shares »

In a regulatory filing,…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 10

    Sep

GLD

SPDR Gold Shares

$144.15

2.77 (1.96%)

17:42
08/23/19
08/23
17:42
08/23/19
17:42
Hot Stocks
SPDR Gold Shares holdings rise to 859.83MT to 854.84MT »

This is the fourth…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

AUMN

Golden Minerals

$0.27

0.0159 (6.38%)

17:33
08/23/19
08/23
17:33
08/23/19
17:33
Hot Stocks
Golden Minerals receives noncompliance notice from NYSE »

Golden Minerals announced…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

DMPI

DelMar Pharmaceuticals

$0.77

0.0047 (0.61%)

17:25
08/23/19
08/23
17:25
08/23/19
17:25
Hot Stocks
Intracoastal Capital reports 9.99% passive stake in DelMar Pharmaceuticals »

Intracoastal Capital…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

RTN

Raytheon

$180.58

-6.44 (-3.44%)

17:22
08/23/19
08/23
17:22
08/23/19
17:22
Hot Stocks
Raytheon awarded $534M Army contract »

Raytheon was awarded a…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

UHAL

Amerco

$339.43

-2.97 (-0.87%)

17:21
08/23/19
08/23
17:21
08/23/19
17:21
Hot Stocks
Amerco announces special cash dividend of 50c per share »

The dividend will be…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

NTLA

Intellia Therapeutics

$15.77

-1.08 (-6.41%)

17:20
08/23/19
08/23
17:20
08/23/19
17:20
Syndicate
Breaking Syndicate news story on Intellia Therapeutics »

Intellia Therapeutics…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

GD

General Dynamics

$183.42

-4.19 (-2.23%)

17:19
08/23/19
08/23
17:19
08/23/19
17:19
Hot Stocks
General Dynamics awarded $1.08B Navy contract modification »

General Dynamics has been…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

NVLN

Novelion Therapeutics

$0.66

-0.0523 (-7.37%)

17:17
08/23/19
08/23
17:17
08/23/19
17:17
Hot Stocks
Stonepine Capital reports 6.1% passive stake in Novelion Therapeutics »

Stonepine Capital…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

LMT

Lockheed Martin

$376.85

-8.91 (-2.31%)

17:14
08/23/19
08/23
17:14
08/23/19
17:14
Hot Stocks
Lockheed Martin awarded $2.43B Navy contract modification »

Lockheed Martin has been…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

ONCS

OncoSec

$1.84

-0.03 (-1.60%)

17:14
08/23/19
08/23
17:14
08/23/19
17:14
Syndicate
Breaking Syndicate news story on OncoSec »

OncoSec files $50M mixed…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

TNXP

Tonix Pharmaceuticals

$0.42

-0.0249 (-5.60%)

17:09
08/23/19
08/23
17:09
08/23/19
17:09
Syndicate
Breaking Syndicate news story on Tonix Pharmaceuticals »

Tonix Pharmaceuticals…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 25

    Sep

SPX

S&P 500

$0.00

(0.00%)

, SPY

SPDR S&P 500 ETF Trust

$284.86

-7.5 (-2.57%)

17:08
08/23/19
08/23
17:08
08/23/19
17:08
General News
Trump to raises tariff rates on Chinese goods, CNBC says »

U.S. President Donald…

SPX

S&P 500

$0.00

(0.00%)

SPY

SPDR S&P 500 ETF Trust

$284.86

-7.5 (-2.57%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

ATIS

Attis Industries

$1.03

-0.08 (-7.21%)

17:06
08/23/19
08/23
17:06
08/23/19
17:06
Hot Stocks
Attis Industries provides update on status of Nasdaq listing »

Attis Industries…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

CVEO

Civeo

$1.32

-0.07 (-5.04%)

17:04
08/23/19
08/23
17:04
08/23/19
17:04
Syndicate
Breaking Syndicate news story on Civeo »

Civeo files $300M mixed…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

AGO

Assured Guaranty

$42.56

-1.09 (-2.50%)

16:58
08/23/19
08/23
16:58
08/23/19
16:58
Hot Stocks
Assured Guaranty CEO sells 30,300 common shares »

In a regulatory filing,…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

RMED

Ra Medical Systems

$1.87

-0.055 (-2.86%)

16:50
08/23/19
08/23
16:50
08/23/19
16:50
Hot Stocks
Ra Medical Systems discloses NYSE notice related to 10-Q filing delay »

Ra Medical Systems…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

PBA

Pembina Pipeline

$35.73

-0.81 (-2.22%)

16:47
08/23/19
08/23
16:47
08/23/19
16:47
Syndicate
Breaking Syndicate news story on Pembina Pipeline »

Pembina Pipeline files…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 01

    Nov

APEN

Apollo Endosurgery

$3.50

(0.00%)

16:44
08/23/19
08/23
16:44
08/23/19
16:44
Syndicate
Breaking Syndicate news story on Apollo Endosurgery »

Apollo Endosurgery files…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

16:40
08/23/19
08/23
16:40
08/23/19
16:40
General news
Fed's Clarida said the global economy has worsened »

Fed's Clarida said…

LQDA

Liquidia Technologies

$5.23

-0.38 (-6.77%)

16:35
08/23/19
08/23
16:35
08/23/19
16:35
Syndicate
Breaking Syndicate news story on Liquidia Technologies »

Liquidia Technologies…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

V

Visa

$175.24

-4.91 (-2.73%)

16:32
08/23/19
08/23
16:32
08/23/19
16:32
Hot Stocks
Visa CFO Prabhu sells over 25,000 class A common shares »

Visa vice chairman and…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 10

    Sep

  • 27

    Oct

QCOM

Qualcomm

$73.57

-3.55 (-4.60%)

16:31
08/23/19
08/23
16:31
08/23/19
16:31
Hot Stocks
Qualcomm CFO Dave Wise to retire, Akash Palkhiwala named interim CFO »

Qualcomm announced that…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 10

    Sep

  • 06

    Nov

ANFI

Amira Nature Foods

$0.58

-0.0144 (-2.44%)

16:30
08/23/19
08/23
16:30
08/23/19
16:30
Hot Stocks
Amira Nature Foods receives NYSE notice over late Form 20-F filing »

Amira Nature Food…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

Get Full Fly Access

Breaking market intelligence sent straight to you
Our team of experts analyze every news story and filter out the noise to deliver real-time market moving news.
Up-to-date information on important industry events
Get real-time updates on events that are moving the market—from conferences and calls to syndicate announcements.
News focused on the companies in your portfolio
Create up to 12 portfolios with 150 stocks each, and see how active they are in market news.